Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 03, 2019 06:00 ET | Source: INSYS Therapeutics, Inc.

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

PHOENIX, July 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its...
June 12, 2019 08:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

PHOENIX, June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June...
June 10, 2019 06:07 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Continue as Normal Including Payment of Employee Wages and...
May 10, 2019 19:05 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Reports First Quarter 2019 Results

Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update PHOENIX, May 10, 2019 ...
April 15, 2019 08:30 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Implements Leadership Changes

PHOENIX, April 15, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
March 25, 2019 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting

PHOENIX, March 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
March 07, 2019 16:15 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results

PHOENIX, March 07, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
March 06, 2019 16:15 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7

PHOENIX, March 06, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
February 25, 2019 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting

PHOENIX, Feb. 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
January 09, 2019 06:00 ET | Source: INSYS Therapeutics, Inc.

INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

PHOENIX, Jan. 09, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...